Table 2 Differentially expressed proteins in mild COVID-19 (n = 5) compared with healthy individuals (n = 10).
From: Saliva changes in composition associated to COVID-19: a preliminary study
Accession (UniProt) | Protein name | Max. no. of quantified peptides | Molecular function | K-W test (P-value) | Dunn’ test for multiple comparison | Regulation in COVID-19 mild disease | |
|---|---|---|---|---|---|---|---|
Log2 fold change | P-value | ||||||
P30838 | Aldehyde dehydrogenase, dimeric NADP-preferring | 2 | 3-chloroallyl aldehyde dehydrogenase activity | 0.01* | −1.29 | 0.006** | Down |
Q8N4F0 | BPI fold-containing family B member 2 | 5 | Lipid binding | 0.003** | −1.19 | 0.01* | Down |
P29508 | Serpin B3 | 5 | Serine-type endopeptidase inhibitor activity | 0.01* | −1.08 | 0.01* | Down |
P12273 | Prolactin-inducible protein | 2 | Actin binding | 0.04* | −0.72 | 0.01* | Down |
P04792 | Heat shock protein beta-1 | 2 | Protein kinase C binding | 0.04* | 1.21 | 0.04* | Up |
P09525 | Annexin A4 | 3 | Calcium ion binding | 0.01* | 1.00 | 0.006** | Up |
Q13510 | Acid ceramidase | 2 | Hydrolase activity | 0.02* | 0.90 | 0.01* | Up |
P52907 | F-actin-capping protein subunit alpha-1 | 2 | Actin binding | 0.04* | 0.79 | 0.01* | Up |
P01619 | Immunoglobulin kappa variable 3–20 | 2 | Antigen binding | 0.02* | 0.72 | 0.009** | Up |
P0C0L4 | Complement C4-A | 6 | Endopeptidase inhibitor activity | 0.04* | 0.71 | 0.01* | Up |